Regenerative Medical Technology (RMTG) Common Equity (2017 - 2026)

Regenerative Medical Technology has reported Common Equity for 10 years, with the latest figure at -$39.3 million in Q2 2026.

• On a quarterly basis, Common Equity fell 35.26% year-over-year to -$39.3 million in Q2 2026; TTM through Jun 2026 was -$39.3 million, a 35.26% decrease from a year earlier, with the FY2025 full-year figure at -$36.0 million, down 31.77% from the prior year.
• Common Equity was -$39.3 million for Q2 2026 at Regenerative Medical Technology, down from -$36.4 million in the prior quarter.
• The five-year high for Common Equity was -$8.2 million in Q1 2022, with the low at -$39.3 million in Q2 2026.
• Average Common Equity over 5 years is -$23.2 million, with a median of -$24.8 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Common Equity tumbled 492.9% in 2022, then fell 12.34% in 2025.
• Over 5 years, Common Equity stood at -$12.0 million in 2022, then plunged by 81.9% to -$21.8 million in 2023, then declined by 25.52% to -$27.4 million in 2024, then sank by 31.77% to -$36.0 million in 2025, then retreated by 8.9% to -$39.3 million in 2026.
• The last three Common Equity figures came in at -$39.3 million (Q2 2026), -$36.4 million (Q1 2026), and -$36.0 million (Q4 2025), per Business Quant data.